{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:44:27Z","timestamp":1790653467979,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Martin-Luther-Universit\u00e4t Halle-Wittenberg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:p>Heart failure is a syndrome that can result from impaired heart muscle contractions like in dilative cardiomyopathy but also from hypertrophic obstructive cardiomyopathy (HOCOM). A pharmacological therapy might lie in Ca<jats:sup>2+<\/jats:sup>-sensitizing or Ca<jats:sup>2+<\/jats:sup>-desensitizing drugs, respectively. Such drugs are thought to be omecamtiv mecarbil (OME) and mavacamten (MYK-461), respectively. Their function in contracting human muscle is not fully understood and was the focus of the present study. OME from 1\u00a0nM to 10\u00a0\u00b5M cumulatively applied failed to raise force of contraction in human right atrial preparations strips (HAP) or mouse left atrial preparations (LA). However, OME prolonged time to peak tension and time of relaxation in HAP and LA but did not alter the beating rate in right atrial preparations from mice (RA). In contrast, MYK-461 (10\u00a0nM to 10\u00a0\u00b5M) reduced concentration- and time-dependently force of contraction in HAP and LA. MYK-461 (10\u00a0\u00b5M) did not affect the beating rate in RA. In summary, the present data failed to detect an increase in force of contraction for OME, in human and mouse atrium. In contrast, a Ca<jats:sup>2+<\/jats:sup> desensitizer studied for comparison was able to reduce force of contraction in HAP and LA. We conclude that putative beneficial effects of OME in dilated cardiomyopathy cannot be explained by positive inotropic effects in the HAP, whereas beneficial functional effects of MYK-461 in HOCOM can be explained by negative inotropic effects in HAP.<\/jats:p>","DOI":"10.1007\/s00210-022-02333-0","type":"journal-article","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T09:43:13Z","timestamp":1668764593000},"page":"499-511","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Effects of omecamtiv mecarbil and mavacamten in isolated human atrium"],"prefix":"10.1007","volume":"396","author":[{"given":"Lina Maria Rayo","family":"Abella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"H\u00f6hm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britt","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Gergs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,18]]},"reference":[{"issue":"9","key":"2333_CR1","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1002\/ejhf.1557","volume":"21","author":"T Ahmad","year":"2019","unstructured":"Ahmad T, Miller PE, McCullough M, Desai NR, Riello R, Psotka M, B\u00f6hm M, Allen LA, Teerlink JR, Rosano GMC, Lindenfeld J (2019) Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials. Eur J Heart Fail 21(9):1064\u20131078. https:\/\/doi.org\/10.1002\/ejhf.1557","journal-title":"Eur J Heart Fail"},{"issue":"24","key":"2333_CR2","doi-asserted-by":"publisher","first-page":"5609","DOI":"10.1111\/bph.15271","volume":"177","author":"PO Awinda","year":"2020","unstructured":"Awinda PO, Bishaw Y, Watanabe M, Guglin MA, Campbell KS, Tanner BCW (2020) Effects of mavacamten on Ca2+ sensitivity of contraction as sarcomere length varied in human myocardium. Br J Pharmacol 177(24):5609\u20135621. https:\/\/doi.org\/10.1111\/bph.15271","journal-title":"Br J Pharmacol"},{"issue":"2","key":"2333_CR3","doi-asserted-by":"publisher","first-page":"H881","DOI":"10.1152\/ajpheart.00345.2020","volume":"320","author":"PO Awinda","year":"2021","unstructured":"Awinda PO, Watanabe M, Bishaw Y, Huckabee AM, Agonias KB, Kazmierczak K, Szczesna-Cordary D, Tanner BCW (2021) Mavacamten decreases maximal force and Ca2+ sensitivity in the N47K-myosin regulatory light chain mouse model of hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol 320(2):H881\u2013H890. https:\/\/doi.org\/10.1152\/ajpheart.00345.2020","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"20","key":"2333_CR4","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1056\/NEJMc2102893","volume":"384","author":"L Bellumkonda","year":"2021","unstructured":"Bellumkonda L (2021) Omecamtiv mecarbil in systolic heart failure. N Engl J Med 384(20):1967. https:\/\/doi.org\/10.1056\/NEJMc2102893","journal-title":"N Engl J Med"},{"issue":"20","key":"2333_CR5","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1056\/NEJMc2102893","volume":"384","author":"S Bonapace","year":"2021","unstructured":"Bonapace S, Molon G (2021) Omecamtiv mecarbil in systolic heart failure. N Engl J Med 384(20):1967. https:\/\/doi.org\/10.1056\/NEJMc2102893","journal-title":"N Engl J Med"},{"issue":"9","key":"2333_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3389\/fphar.2018.00013","volume":"22","author":"P Boknik","year":"2018","unstructured":"Boknik P, Drzewiecki K, Eskandar J, Gergs U, Grote-Wessels S, Fabritz L, Kirchhof P, M\u00fcller FU, St\u00fcmpel F, Schmitz W, Zimmermann N, Kirchhefer U, Neumann J (2018) Phenotyping of mice with heart specific overexpression of A2A-adenosine receptors: evidence for cardioprotective effects of A2A-adenosine receptors. Front Pharmacol 22(9):13. https:\/\/doi.org\/10.3389\/fphar.2018.00013","journal-title":"Front Pharmacol"},{"issue":"2","key":"2333_CR7","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1093\/toxsci\/kfv062","volume":"145","author":"L Butler","year":"2015","unstructured":"Butler L, Cros C, Oldman KL, Harmer AR, Pointon A, Pollard CE, Abi-Gerges N (2015) Enhanced characterization of contractility in cardiomyocytes during early drug safety assessment. Toxicol Sci 145(2):396\u2013406. https:\/\/doi.org\/10.1093\/toxsci\/kfv062 (Epub 2015 Mar 29)","journal-title":"Toxicol Sci"},{"issue":"3","key":"2333_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.760","volume":"9","author":"A Dashwood","year":"2021","unstructured":"Dashwood A, Cheesman E, Wong YW, Haqqani H, Beard N, Hay K, Spratt M, Chan W, Molenaar P (2021) Effects of omecamtiv mecarbil on failing human ventricular trabeculae and interaction with (-)-noradrenaline. Pharmacol Res Perspect 9(3):e00760. https:\/\/doi.org\/10.1002\/prp2.760","journal-title":"Pharmacol Res Perspect"},{"key":"2333_CR9","doi-asserted-by":"publisher","unstructured":"Endoh M. Does levosimendan act as a Ca2+\u00a0sensitizer or PDE3 inhibitor?: Commentary on Orstavik et\u2009al., Br J Pharmacol 171: 5169\u20135181. Br J Pharmacol. 2015 Sep;172(18):4594\u20134596. https:\/\/doi.org\/10.1111\/bph.12649.","DOI":"10.1111\/bph.12649"},{"issue":"1","key":"2333_CR10","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s00395-021-00866-8","volume":"116","author":"G\u00c1 F\u00fcl\u00f6p","year":"2021","unstructured":"F\u00fcl\u00f6p G\u00c1, Ol\u00e1h A, Csipo T, Kov\u00e1cs \u00c1, P\u00f3rsz\u00e1sz R, Veress R, Horv\u00e1th B, Nagy L, B\u00f3di B, Fagyas M, Helgadottir SL, B\u00e1nhegyi V, Juh\u00e1sz B, Bombicz M, Priksz D, Nanasi P Jr, Merkely B, \u00c9des I, Csan\u00e1di Z, Papp Z, Radovits T, T\u00f3th A (2021) Omecamtiv mecarbil evokes diastolic dysfunction and leads to periodic electromechanical alternans. Basic Res Cardiol 116(1):24. https:\/\/doi.org\/10.1007\/s00395-021-00866-8","journal-title":"Basic Res Cardiol"},{"issue":"5","key":"2333_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.656","volume":"8","author":"BX Gao","year":"2020","unstructured":"Gao BX, Sutherland W, Vargas HM, Qu Y (2020) Effects of omecamtiv mecarbil on calcium-transients and contractility in a translational canine myocyte model. Pharmacol Res Perspect 8(5):e00656. https:\/\/doi.org\/10.1002\/prp2.656","journal-title":"Pharmacol Res Perspect"},{"key":"2333_CR12","doi-asserted-by":"publisher","unstructured":"Gergs U, Bernhardt G, Buchwalow IB, Edler H, Fr\u00f6ba J, Keller M, Kirchhefer U, K\u00f6hler F, Mi\u00dflinger N, Wache H, Neumann J. Initial characterization of transgenic mice overexpressing human histamine H2 receptors. J Pharmacol Exp Ther. 2019a Apr;369(1):129-141. https:\/\/doi.org\/10.1124\/jpet.118.255711.","DOI":"10.1124\/jpet.118.255711"},{"key":"2333_CR13","doi-asserted-by":"publisher","unstructured":"Gergs U, B\u00f6ckler A, Ebelt H, Hauptmann S, Keller N, Otto V, P\u00f6nicke K, Schmitz W, Neumann J. Human 5-HT4receptor stimulation in atria of transgenic mice. Naunyn Schmiedebergs Arch Pharmacol. 2013 May;386(5):357-67. https:\/\/doi.org\/10.1007\/s00210-013-0831-x","DOI":"10.1007\/s00210-013-0831-x"},{"issue":"3","key":"2333_CR14","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/apha.12766","volume":"219","author":"U Gergs","year":"2017","unstructured":"Gergs U, Fahrion CM, Bock P, Fischer M, Wache H, Hauptmann S, Schmitz W, Neumann J (2017) Evidence for a functional role of calsequestrin 2 in mouse atrium. Acta Physiol (oxf) 219(3):669\u2013682. https:\/\/doi.org\/10.1111\/apha.12766","journal-title":"Acta Physiol (oxf)"},{"issue":"4","key":"2333_CR15","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s00210-008-0371-y","volume":"379","author":"U Gergs","year":"2009","unstructured":"Gergs U, Neumann J, Simm A, Silber RE, Remmers FO, L\u00e4er S (2009) Phosphorylation of phospholamban and troponin I through 5-HT4 receptors in the isolated human atrium. Naunyn Schmiedebergs Arch Pharmacol 379(4):349\u2013359. https:\/\/doi.org\/10.1007\/s00210-008-0371-y","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2333_CR16","doi-asserted-by":"publisher","unstructured":"Gergs U, Trapp T, Bushnaq H, Simm A, Silber RE, Neumann J. Age-dependent protein expression of serine\/threonine phosphatases and their inhibitors in the human cardiac atrium. Adv Med. 2019b Jan 2;2019b:2675972. https:\/\/doi.org\/10.1155\/2019\/2675972.","DOI":"10.1155\/2019\/2675972"},{"issue":"6273","key":"2333_CR17","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1126\/science.aad3456","volume":"351","author":"EM Green","year":"2016","unstructured":"Green EM, Wakimoto H, Anderson RL, Evanchik MJ, Gorham JM, Harrison BC, Henze M, Kawas R, Oslob JD, Rodriguez HM, Song Y, Wan W, Leinwand LA, Spudich JA, McDowell RS, Seidman JG, Seidman CE (2016) A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science 351(6273):617\u2013621. https:\/\/doi.org\/10.1126\/science.aad3456","journal-title":"Science"},{"issue":"20","key":"2333_CR18","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1056\/NEJMc2102893","volume":"384","author":"K Komamura","year":"2021","unstructured":"Komamura K (2021) Omecamtiv mecarbil in systolic heart failure. N Engl J Med 384(20):1966\u20131967. https:\/\/doi.org\/10.1056\/NEJMc2102893","journal-title":"N Engl J Med"},{"issue":"1","key":"2333_CR19","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/1440-1681.13584","volume":"49","author":"O Lookin","year":"2022","unstructured":"Lookin O, Kuznetsov D, Protsenko Y (2022) Omecamtiv mecarbil attenuates length-tension relationship in healthy rat myocardium and preserves it in monocrotaline-induced pulmonary heart failure. Clin Exp Pharmacol Physiol 49(1):84\u201393. https:\/\/doi.org\/10.1111\/1440-1681.13584","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"44","key":"2333_CR20","doi-asserted-by":"publisher","first-page":"3626","DOI":"10.1093\/eurheartj\/ehy600","volume":"40","author":"C Maack","year":"2019","unstructured":"Maack C, Eschenhagen T, Hamdani N, Heinzel FR, Lyon AR, Manstein DJ, Metzger J, Papp Z, Tocchetti CG, Yilmaz MB, Anker SD, Balligand JL, Bauersachs J, Brutsaert D, Carrier L, Chlopicki S, Cleland JG, de Boer RA, Dietl A, Fischmeister R, Harjola VP, Heymans S, Hilfiker-Kleiner D, Holzmeister J, de Keulenaer G, Limongelli G, Linke WA, Lund LH, Masip J, Metra M, Mueller C, Pieske B, Ponikowski P, Risti\u0107 A, Ruschitzka F, Seferovi\u0107 PM, Skouri H, Zimmermann WH, Mebazaa A (2019) Treatments targeting inotropy. Eur Heart J 40(44):3626\u20133644. https:\/\/doi.org\/10.1093\/eurheartj\/ehy600","journal-title":"Eur Heart J"},{"issue":"6023","key":"2333_CR21","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1126\/science.1200113","volume":"331","author":"FI Malik","year":"2011","unstructured":"Malik FI, Hartman JJ, Elias KA, Morgan BP, Rodriguez H, Brejc K, Anderson RL, Sueoka SH, Lee KH, Finer JT, Sakowicz R, Baliga R, Cox DR, Garard M, Godinez G, Kawas R, Kraynack E, Lenzi D, Lu PP, Muci A, Niu C, Qian X, Pierce DW, Pokrovskii M, Suehiro I, Sylvester S, Tochimoto T, Valdez C, Wang W, Katori T, Kass DA, Shen YT, Vatner SF, Morgans DJ (2011) Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science 331(6023):1439\u20131443. https:\/\/doi.org\/10.1126\/science.1200113","journal-title":"Science"},{"key":"2333_CR22","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.yjmcc.2015.06.011","volume":"85","author":"R Mamidi","year":"2015","unstructured":"Mamidi R, Gresham KS, Li A, dos Remedios CG, Stelzer JE (2015) Molecular effects of the myosin activator omecamtiv mecarbil on contractile properties of skinned myocardium lacking cardiac myosin binding protein-C. J Mol Cell Cardiol 85:262\u2013272. https:\/\/doi.org\/10.1016\/j.yjmcc.2015.06.011","journal-title":"J Mol Cell Cardiol"},{"issue":"7","key":"2333_CR23","doi-asserted-by":"publisher","DOI":"10.1085\/jgp.202012816","volume":"153","author":"R Mamidi","year":"2021","unstructured":"Mamidi R, Holmes JB, Doh CY, Dominic KL, Madugula N, Stelzer JE (2021) cMyBPC phosphorylation modulates the effect of omecamtiv mecarbil on myocardial force generation. J Gen Physiol 153(7):e202012816. https:\/\/doi.org\/10.1085\/jgp.202012816","journal-title":"J Gen Physiol"},{"issue":"10","key":"2333_CR24","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.117.004257","volume":"10","author":"R Mamidi","year":"2017","unstructured":"Mamidi R, Li J, Gresham KS, Verma S, Doh CY, Li A, Lal S, Dos Remedios CG, Stelzer JE (2017) Dose-dependent effects of the myosin activator omecamtiv mecarbil on cross-bridge behavior and force generation in failing human myocardium. Circ Heart Fail 10(10):e004257. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.117.004257","journal-title":"Circ Heart Fail"},{"issue":"18","key":"2333_CR25","doi-asserted-by":"publisher","first-page":"4506","DOI":"10.1111\/bph.13235","volume":"172","author":"L Nagy","year":"2015","unstructured":"Nagy L, Kov\u00e1cs \u00c1, B\u00f3di B, P\u00e1sztor ET, F\u00fcl\u00f6p G\u00c1, T\u00f3th A, \u00c9des I, Papp Z (2015) The novel cardiac myosin activator omecamtiv mecarbil increases the calcium sensitivity of force production in isolated cardiomyocytes and skeletal muscle fibres of the rat. Br J Pharmacol 172(18):4506\u20134518. https:\/\/doi.org\/10.1111\/bph.13235","journal-title":"Br J Pharmacol"},{"key":"2333_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2021.110035","volume":"85","author":"J Neumann","year":"2021","unstructured":"Neumann J, Boknik P, Kirchhefer U, Gergs U (2021a) The role of PP5 and PP2C in cardiac health and disease. Cell Signal 85:110035. https:\/\/doi.org\/10.1016\/j.cellsig.2021.110035","journal-title":"Cell Signal"},{"issue":"1","key":"2333_CR27","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/sj.bjp.0705012","volume":"138","author":"J Neumann","year":"2003","unstructured":"Neumann J, Boknik P, Matherne GP, Lankford A, Schmitz W (2003) Pertussis toxin sensitive and insensitive effects of adenosine and carbachol in murine atria overexpressing A(1)-adenosine receptors. Br J Pharmacol 138(1):209\u2013217. https:\/\/doi.org\/10.1038\/sj.bjp.0705012","journal-title":"Br J Pharmacol"},{"issue":"3","key":"2333_CR28","first-page":"1579","volume":"277","author":"J Neumann","year":"1996","unstructured":"Neumann J, Eschenhagen T, Grupp IL, Haverich A, Herzig JW, Hirt S, Kalm\u00e1r P, Schmitz W, Scholz H, Stein B, Wenzlaff H, Zimmermann N (1996) Positive inotropic effects of the calcium sensitizer CGP 48506 in failing human myocardium. J Pharmacol Exp Ther 277(3):1579\u20131585","journal-title":"J Pharmacol Exp Ther"},{"issue":"12","key":"2333_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.582916","volume":"11","author":"J Neumann","year":"2021","unstructured":"Neumann J, Grobe JM, Weisgut J, Schwelberger HG, Fogel WA, Maru\u0161\u00e1kov\u00e1 M, Wache H, B\u00e4hre H, Buchwalow IB, Dhein S, Hofmann B, Kirchhefer U, Gergs U (2021b) Histamine can be formed and degraded in the human and mouse heart. Front Pharmacol 11(12):582916. https:\/\/doi.org\/10.3389\/fphar.2021.582916","journal-title":"Front Pharmacol"},{"key":"2333_CR30","doi-asserted-by":"publisher","unstructured":"Olivotto I, Oreziak A, Barriales-Villa R, Abraham TP, Masri A, Garcia-Pavia P, Saberi S, Lakdawala NK, Wheeler MT, Owens A, Kubanek M, Wojakowski W, Jensen MK, Gimeno-Blanes J, Afshar K, Myers J, Hegde SM, Solomon SD, Sehnert AJ, Zhang D, Li W, Bhattacharya M, Edelberg JM, Waldman CB, Lester SJ, Wang A, Ho CY, Jacoby D; EXPLORER-HCM study investigators. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020 Sep 12;396(10253):759\u2013769. https:\/\/doi.org\/10.1016\/S0140-6736(20)31792-X.","DOI":"10.1016\/S0140-6736(20)31792-X"},{"issue":"23","key":"2333_CR31","doi-asserted-by":"publisher","first-page":"5169","DOI":"10.1111\/bph.12647","volume":"171","author":"O Orstavik","year":"2014","unstructured":"Orstavik O, Ata SH, Riise J, Dahl CP, Andersen G\u00d8, Levy FO, Skomedal T, Osnes JB, Qvigstad E (2014) Inhibition of phosphodiesterase-3 by levosimendan is sufficient to account for its inotropic effect in failing human heart. Br J Pharmacol 171(23):5169\u20135181. https:\/\/doi.org\/10.1111\/bph.12647","journal-title":"Br J Pharmacol"},{"issue":"3","key":"2333_CR32","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1161\/01.res.51.3.290","volume":"51","author":"RJ Solaro","year":"1982","unstructured":"Solaro RJ, R\u00fcegg JC (1982) Stimulation of Ca++ binding and ATPase activity of dog cardiac myofibrils by AR-L 115BS, a novel cardiotonic agent. Circ Res 51(3):290\u2013294. https:\/\/doi.org\/10.1161\/01.res.51.3.290","journal-title":"Circ Res"},{"issue":"4","key":"2333_CR33","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1161\/CIRCHEARTFAILURE.109.930321","volume":"3","author":"YT Shen","year":"2010","unstructured":"Shen YT, Malik FI, Zhao X, Depre C, Dhar SK, Abarz\u00faa P, Morgans DJ, Vatner SF (2010) Improvement of cardiac function by a cardiac myosin activator in conscious dogs with systolic heart failure. Circ Heart Fail 3(4):522\u2013527. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.109.930321","journal-title":"Circ Heart Fail"},{"issue":"12","key":"2333_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0168407","volume":"11","author":"JA Stern","year":"2016","unstructured":"Stern JA, Markova S, Ueda Y, Kim JB, Pascoe PJ, Evanchik MJ, Green EM, Harris SP (2016) A small molecule inhibitor of sarcomere contractility acutely relieves left ventricular outflow tract obstruction in feline hypertrophic cardiomyopathy. PLoS ONE 11(12):e0168407. https:\/\/doi.org\/10.1371\/journal.pone.0168407","journal-title":"PLoS ONE"},{"key":"2333_CR35","doi-asserted-by":"publisher","unstructured":"Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, Adams KF, Anand I, Arias-Mendoza A, Biering-S\u00f8rensen T, B\u00f6hm M, Bonderman D, Cleland JGF, Corbalan R, Crespo-Leiro MG, Dahlstr\u00f6m U, Echeverria Correa LE, Fang JC, Filippatos G, Fonseca C, Goncalvesova E, Goudev AR, Howlett JG, Lanfear DE, Lund M, Macdonald P, Mareev V, Momomura SI, O'Meara E, Parkhomenko A, Ponikowski P, Ramires FJA, Serpytis P, Sliwa K, Spinar J, Suter TM, Tomcsanyi J, Vandekerckhove H, Vinereanu D, Voors AA, Yilmaz MB, Zannad F, Sharpsten L, Legg JC, Abbasi SA, Varin C, Malik FI, Kurtz CE; GALACTIC-HF Investigators. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials. Eur J Heart Fail. 2020 Nov;22(11):2160\u20132171. https:\/\/doi.org\/10.1002\/ejhf.2015. Epub 2020 Oct 27. Erratum in: Eur J Heart Fail. 2021 Dec 20","DOI":"10.1002\/ejhf.2015"},{"key":"2333_CR36","doi-asserted-by":"publisher","unstructured":"Teerlink JR, Felker GM, McMurray JJ, Solomon SD, Adams KF Jr, Cleland JG, Ezekowitz JA, Goudev A, Macdonald P, Metra M, Mitrovic V, Ponikowski P, Serpytis P, Spinar J, Tomcs\u00e1nyi J, Vandekerckhove HJ, Voors AA, Monsalvo ML, Johnston J, Malik FI, Honarpour N; COSMIC-HF Investigators. Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet. 2016 Dec 10;388(10062):2895\u20132903. https:\/\/doi.org\/10.1016\/S0140-6736(16)32049-9.","DOI":"10.1016\/S0140-6736(16)32049-9"},{"issue":"3","key":"2333_CR37","first-page":"1572","volume":"277","author":"N Zimmermann","year":"1996","unstructured":"Zimmermann N, Bokn\u00edk P, Gams E, Herzig JW, Neumann J, Schmitz W, Scholz H, Wenzlaff H (1996) Positive inotropic effects of the calcium sensitizer CGP 48506 in guinea pig myocardium. J Pharmacol Exp Ther 277(3):1572\u20131578","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"2333_CR38","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/s1010-7940(98)00129-8","volume":"14","author":"N Zimmermann","year":"1998","unstructured":"Zimmermann N, Boknik P, Gams E, Herzig JW, Neumann J, Scholz H (1998) Calcium sensitization as new principle of inotropic therapy in end-stage heart failure? Eur J Cardiothorac Surg 14(1):70\u201375. https:\/\/doi.org\/10.1016\/s1010-7940(98)00129-8","journal-title":"Eur J Cardiothorac Surg"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-022-02333-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-022-02333-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-022-02333-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T06:09:03Z","timestamp":1675404543000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-022-02333-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,18]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["2333"],"URL":"https:\/\/doi.org\/10.1007\/s00210-022-02333-0","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,18]]},"assertion":[{"value":"20 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animals: The investigation conformed to the <i>Guide for the Care and Use of Laboratory Animals<\/i> as published by the National Research Council (2011). The animals were handled and maintained according to the approved protocols of the Animal Welfare Committee of the University of Halle-Wittenberg, Halle, Germany.Humans: This study complies with the Declaration of Helsinki and has been approved by the local ethics committee (hm-b\u00fc 04.08.2005).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all patients included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors declare that they have seen and approved the submitted version of this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}